Research Article
Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones
Table 5
In vivo efficacy log10 CFU reduction in bacterial load in lungs and spleen.
| Test group | Organ | Dose mg/Kg/dy | Mean ± SEM CFU | reduction | Activity |
| Untreated d13 | Lung | n/a | 6.90 ± 0.11 | n/a | n/a | Spleen | 4.75 ± 0.21 |
| Untreated d22 | Lung | n/a | 8.06 ± 0.11 | n/a | n/a | Spleen | 6.38 ± 0.07 |
| INH | Lung | 25 | 4.77 ± 0.12 | 3.29 | Active | Spleen | 2.04 ± 0.38 | 4.34 | Active |
| 2l (306019) | Lung | 150 | 7.67 ± 0.22 | 0.39 | Inactivea | Spleen | 6.24 ± 0.06 | 0.14 | Inactivea |
| 1g (306027) | Lung | 300 | 7.28 ± 0.14 | 0.78 | Slightly active | Spleen | 5.95 ± 0.09 | 0.43 | Inactivea |
| PH-27 (306006) | Lung | 150 | 6.62 ± 0.08 | 1.44 | Active | Spleen | 4.64 ± 0.21 | 1.74 | Active |
|
|
a306027: slightly active in lung, but activity in spleen was not statistically significant.
|